AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China
$1.2bn Validation Of Chinese Capabilities
The UK drug maker’s latest deal marks the largest China biotech M&A deal to date, amid the lingering doom and gloom surrounding the fast emerging but cash-constrained sector.
